Avalon Trust’s Nuvectis Pharma NVCT Stock Holding History

Avalon Trust’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$108K	Hold	14,000	–	–	0.01%	209
2025 Q4	$106K	Buy	14,000 +4,000	+40%	+$26.1K	0.01%	196
2025 Q3	$60.2K	Buy	+10,000	New	+$68.7K	﹤0.01%	293

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Avalon Trust's NVCT Position: Q1 2026 in Review

Avalon Trust held its Nuvectis Pharma (NVCT) position steady in Q1 2026 at 14,000 shares worth $108K. The position accounts for 0.01% of the portfolio, ranked #209.

Avalon Trust first reported a position in NVCT in Q3 2025 and has held it in 3 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

Avalon Trust held 14,000 shares of Nuvectis Pharma worth $108K as of Q1 2026.
Avalon Trust left its Nuvectis Pharma share count unchanged in Q1 2026.
Nuvectis Pharma made up 0.01% of Avalon Trust's portfolio in Q1 2026, its #209 holding.
Avalon Trust first reported a position in Nuvectis Pharma in Q3 2025 and has held it in 3 quarters since.
62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Avalon Trust's 13F filing for Q1 2026, filed 6 May 2026.